SCHEMBL21807100

SCHEMBL21807100

COC(=O)Cc1cccc(OC2CC2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.50
HRH1 P35367 1/20 0.50
SLC7A5 Q01650 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.45
SIGMAR1 Q99720 2/20 0.44
HDAC4 P56524 2/20 0.44
MEF2D Q14814 2/20 0.44
OPRK1 P41145 1/20 0.43
MAPT P10636 1/20 0.43
MAPK1 P28482 1/20 0.43
ALDH1A1 P00352 1/20 0.43
GAA P10253 1/20 0.43
GFER P55789 1/20 0.43
CCNA2 P20248 1/20 0.43
CDK2 P24941 1/20 0.43
CCNA1 P78396 1/20 0.43
EP300 Q09472 1/20 0.43
CTBP2 P56545 1/20 0.43
HSP90AB1 P08238 1/20 0.42
SLC5A7 Q9GZV3 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12985373 0.83 HRH1 (0.53) HRH1HDAC4MEF2DOPRK1EP300
SCHEMBL3964624 0.83 CYP19A1 (0.54) POLBHRH1SIGMAR1HDAC4MEF2D
SCHEMBL17112399 0.82 POLB (0.41) POLBHRH1SIGMAR1MAPTMAPK1
SCHEMBL16828657 0.81 CYP4F2 (0.53) MAPTALDH1A1GAAGFERHSP90AB1
SCHEMBL378705 0.81 SMN1; SMN2 (0.61) POLBSLC7A5SMN1; SMN2ALDH1A1CTBP2
SCHEMBL31249652 0.81 SMN1; SMN2 (0.61) POLBSLC7A5SMN1; SMN2ALDH1A1CTBP2
SCHEMBL22365344 0.80 HRH1 (0.58) HRH1MAPTMAPK1
SCHEMBL2767480 0.80 SMN1; SMN2 (0.53) SLC7A5SMN1; SMN2MAPTMAPK1ALDH1A1
SCHEMBL16920641 0.80 PTGS1 (0.46) SMN1; SMN2MAPTALDH1A1GAAGFER
SCHEMBL17321008 0.79 HSP90AB1 (0.46) POLBSMN1; SMN2OPRK1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230065368-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. 2023-03-02 US disclosed
US-20230065368-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. 2023-03-02 US disclosed
EP-3852790-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X Forma Therapeutics, Inc. (US) 2021-07-28 EP disclosed
CN-113164571-A Inhibition of ubiquitin-specific peptidase 9X 福马治疗股份有限公司 2021-07-23 CN disclosed
WO-2020061261-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. (US) 2020-03-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230065368-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X USP9X, USP19, USP39 POLB 2574/4885HRH1 3260/4885SLC7A5 4217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.